BOTHELL, Wash., July 11, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered via infusion, announced today that it intends to offer and sell, subject to market and other conditions, 12,500,000 shares of its common stock in an underwritten public offering. In connection with this offering, Alder BioPharmaceuticals, Inc. expects to grant the underwriters a 30-day option to purchase up to 1,875,000 additional shares of common stock.
Alder intends to use the net proceeds from the offering, together with other available funds, to fund the continued development of eptinezumab, including completion of the ongoing infusion pivotal trial program, the planned submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), establishment of the commercial drug supply chain and other commercialization activities, and for working capital and general corporate purposes.
Leerink Partners LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. Needham & Company, LLC is acting as co-manager for the offering.
A shelf registration statement relating to the offering was filed with the Securities and Exchange Commission (SEC), and was effective on filing on February 23, 2017. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from Leerink Partners LLC, Attn: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132 or by email at email@example.com; or from Wells Fargo Securities, LLC, Attn: Equity Syndicate Department, 375 Park Avenue, New York, NY 10152, by telephone at (800) 326-5897 or by email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Alder’s expectations regarding the completion, timing and size of the public offering, its expectations with respect to granting the underwriters a 30-day option to purchase additional shares, its anticipated use of net proceeds from the offering, and the continued development of eptinezumab, including completion of the ongoing infusion pivotal trial program, the planned submission of a BLA submission to the FDA and establishment of the commercial drug supply chain. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties related to completion of the public offering on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the public offering. More information about the risks and uncertainties faced by Alder is contained in the section captioned “Risk Factors” in the preliminary prospectus supplement related to the public offering filed with the Securities and Exchange Commission (SEC) and other filings with the SEC from time to time. Alder disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source:Alder BioPharmaceuticals, Inc.